Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Docetaxel and Lidocaine Co-Loaded (NLC-in-Hydrogel) Hybrid System Designed for the Treatment of Melanoma

Full text
Author(s):
de Moura, Ludmilla David [1] ; Ribeiro, Ligia N. M. [1, 2] ; de Carvalho, Fabiola V. [1] ; Rodrigues da Silva, Gustavo H. [1] ; Lima Fernandes, Priscila C. [1] ; Brunetto, Sergio Q. [3] ; Ramos, Celso D. [3] ; Velloso, Licio A. [4] ; de Araujo, Daniele R. [5] ; de Paula, Eneida [1]
Total Authors: 10
Affiliation:
[1] Univ Campinas UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, BR-13083862 Campinas, SP - Brazil
[2] Fed Univ Uberlandia UFU, Inst Biotechnol, BR-38405319 Uberlandia, MG - Brazil
[3] Univ Campinas UNICAMP, Dept Radiol, BR-13083887 Campinas, SP - Brazil
[4] Univ Campinas UNICAMP, Sch Med Sci, Dept Clin Med, BR-13083887 Campinas, SP - Brazil
[5] ABC Fed Univ UFABC, Human & Nat Sci Ctr, BR-09210580 Santo Andre, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: PHARMACEUTICS; v. 13, n. 10 OCT 2021.
Web of Science Citations: 0
Abstract

Melanoma is the most aggressive skin carcinoma and nanotechnology can bring new options for its pharmacological treatment. Nanostructured lipid carriers (NLC) are ideal drug-delivery carriers for hydrophobic drugs, such as the antineoplastic docetaxel (DTX), and hybrid (NLC-in-hydrogel) systems are suitable for topical application. This work describes a formulation of NLCDTX in xanthan-chitosan hydrogel containing lidocaine (LDC) with anticancer and analgesia effects. The optimized nanoparticles encapsulated 96% DTX and rheological analysis revealed inherent viscoelastic properties of the hydrogel. In vitro assays over murine fibroblasts (NIH/3T3) and melanoma cells (B16-F10), human keratinocytes (HaCaT) and melanoma cells (SK-MEL-103) showed reduction of docetaxel cytotoxicity after encapsulation in NLCDTX and HGel-NLCDTX. Addition of LDC to the hybrid system (HGel-NLCDTX-LDC) increased cell death in tumor and normal cells. In vivo tests on C57BL/6J mice with B16-F10-induced melanoma indicated that LDC, NLCDTX, HGel-NLCDTX-LDC and NLCDTX + HGel-LDC significantly inhibited tumor growth while microPET/SPECT/CT data suggest better prognosis with the hybrid treatment. No adverse effects were observed in cell survival, weight/feed-consumption or serum biochemical markers (ALT, AST, creatinine, urea) of animals treated with NLCDTX or the hybrid system. These results confirm the adjuvant antitumor effect of lidocaine and endorse HGel-NLCDTX-LDC as a promising formulation for the topical treatment of melanoma.</p> (AU)

FAPESP's process: 19/17784-0 - Plasma pharmacokinetics and tissue biodistribution of lipid-based nanoformulations
Grantee:Eneida de Paula
Support Opportunities: Regular Research Grants